Alzheimer’s Disease — SCF-PCR Platform Mapped to FDA-Approved Therapeutics

Program: PROJECT NEURO-ORIGINIS

Platform Codename: SCF-PCR-ALZ-Ω

Therapeutic Architecture: Preventative → Curative → Restorative (PCR Braid)

Framework: Synergistic Compatibility Framework (SCF)

I. PLATFORM OBJECTIVE

To convert the three SCF API Discovery Profiles

NO-API-Θ1 — Neuroenergetic–Epigenomic Interceptor
NO-API-Θ2 — Neuroimmune–Network Stabilizer
NO-API-Φ-ALZ — Neurostructural Restoration Agent

into a translational SCF Biotech Systems Therapeutic Platform mapped to existing FDA-approved drug classes to enable:

IND-defensible translational programs
mechanistic validation using approved molecules
accelerated clinical development

The platform follows the SCF-PCR therapeutic braid, a systems-level intervention sequence addressing upstream disease drivers rather than downstream protein pathology.

II. SCF PATHOGENESIS MODEL FOR ALZHEIMER’S DISEASE

Etiopathogenic Core

Alzheimer’s prodrome arises from a cascade of systemic failures:

SCF Fault Tier	Biological Dysfunction	Clinical Outcome
Tier 1	Epigenomic plasticity collapse	Learning gene suppression
Tier 2	Mitochondrial bioenergetic failure	Neuronal energy deficit
Tier 3	Neuroimmune dysregulation	Microglial priming
Tier 4	Structural degeneration	Synaptic and myelin loss
Tier 5	Network desynchronization	Cognitive decline

The SCF platform intervenes upstream of amyloid/tau pathology.

III. SCF-PCR PLATFORM THERAPEUTIC ARCHITECTURE

Platform Structure

SCF Module	API	Biological Role	PCR Mode
Module A	Θ1	Epigenomic + mitochondrial interception	Preventative
Module B	Θ2	Immune resolution + network stabilization	Curative
Module C	Φ-ALZ	Structural and network restoration	Restorative

The modules form a biological cascade:

Energy restoration → Immune stabilization → Structural regeneration

IV. FDA DRUG MAPPING TO SCF PLATFORM

Existing FDA-approved drugs map mechanistically to SCF therapeutic nodes, enabling translational validation.

V. MODULE A — PREVENTATIVE INTERCEPTION ENGINE

(Mapped to NO-API-Θ1)

Biological Targets

Epigenomic drift
Chronobiologic disruption
Early autonomic instability

FDA Drug Class Mapping

Therapeutic Class	SCF Target	FDA-Approved Drugs
AhR pathway modulation	Reduce stress-viral transcription	Omeprazole
Epigenetic normalization	HDAC bias correction	Valproate, Vorinostat
Circadian rhythm restoration	Chronobiologic alignment	Melatonin, Tasimelteon
Early ANS stabilization	Reduce sympathetic overdrive	Propranolol, Ivabradine

Functional Outcome

Reopens transcriptional plasticity
prevents neuroimmune shock escalation
stabilizes neuronal metabolic environment

VI. MODULE B — CURATIVE CORE

(Mapped to NO-API-Θ2)

Biological Targets

mitochondrial collapse
autonomic dysregulation
neuroimmune misidentification

FDA Drug Class Mapping

Therapeutic Class	SCF Target	FDA-Approved Drugs
Mitochondrial metabolic restoration	ATP / NAD⁺ recovery	Nicotinamide riboside, CoQ10
Mitochondrial biogenesis signaling	PGC-1α activation	Metformin
Mitophagy regulation	Remove damaged mitochondria	Urolithin A (late-stage clinical)
Autonomic stabilization	Vagal tone recovery	Pyridostigmine, Midodrine
Neuroimmune tolerance restoration	Microglial reprogramming	Minocycline, Colchicine
Neuroendocrine regulation	HPA axis normalization	Mifepristone, Hydrocortisone

Functional Outcome

restores mitochondrial bioenergetics
resolves inflammatory signaling noise
stabilizes autonomic–immune governance

VII. MODULE C — RESTORATIVE ENGINE

(Mapped to NO-API-Φ-ALZ)

Biological Targets

synaptic degeneration
demyelination
circuit desynchronization

FDA Drug Class Mapping

Therapeutic Class	SCF Target	FDA-Approved Drugs
Anti-apoptotic metabolic stabilizers	Neuronal survival	Memantine
Neuroplasticity modulators	Learning restoration	Fluoxetine, D-cycloserine
Remyelination support	Oligodendrocyte recovery	Clemastine fumarate
Synaptic network stabilization	Circuit coherence	Donepezil
Prefrontal-ANS integration	Cognitive-autonomic coupling	Guanfacine

Functional Outcome

restores white-matter integrity
stabilizes synaptic architecture
improves neural network synchrony

VIII. INTEGRATED PLATFORM SYNERGY

SCF TRI-API SYSTEM

Platform Phase	Primary System	Expected Effect
Preventative	Epigenomic + metabolic	halt disease initiation
Curative	Neuroimmune + autonomic	reverse causal dysfunction
Restorative	Structural + network	rebuild cognitive resilience

SCF SYNERGY METRICS

Metric	Function
TSSM	Multi-axis therapeutic pressure
HSV-F²	Metabolic efficiency
SV-EQ	Target specificity
MGIS	Pharmacokinetic geometry alignment
SPCI	Safety compatibility

These metrics form the five-pillar SCF synergy architecture governing platform design.

IX. CLINICAL TRANSLATION STRATEGY

IND-Ready Development Model

Stage	Objective
Preclinical	Molecular validation and synergy modeling
IND	Regulatory authorization for human trials
Phase I	Safety and PK/PD
Phase II	Biomarker and cognitive efficacy
Phase III	Disease-modifying confirmation

The platform can leverage existing FDA-approved molecules for early translational testing, accelerating development timelines.

X. SYSTEMS-LEVEL THERAPEUTIC IMPACT

Expected clinical improvements include:

Domain	Impact
Cognitive	Stabilized memory and executive function
Neuroimmune	Reduced inflammatory tone
Structural	Preserved white-matter integrity
Bioenergetic	Restored neuronal ATP capacity
Network	Improved brain oscillatory coherence

XI. STRATEGIC ADVANTAGE

The SCF-PCR Alzheimer’s Platform offers several translational advantages:

Systems-level disease interception
Multi-pathway therapeutic synergy
FDA-mapped drug validation
High resistance barrier
IND-defensible mechanistic architecture

XII. PLATFORM SUMMARY

SCF-PCR-ALZ-Ω

A biotech systems therapeutic platform integrating:

epigenomic interception
mitochondrial restoration
immune stabilization
structural neural repair

into a Preventative–Curative–Restorative therapeutic cascade mapped to both novel SCF APIs and FDA-approved mechanistic drug classes.

This architecture enables rapid translational validation while supporting development of next-generation disease-modifying therapeutics for Alzheimer’s disease.

MASTER INDEX REGISTRY

Platform Code: SCF-PCR-ALZ-Ω

Program: PROJECT NEURO-ORIGINIS

Document Code: SCF-RD-ALZ-PCR-FDA-MAP-0002

Classification: SCF Biotech Systems Therapeutic Platform

Framework: Synergistic Compatibility Framework (SCF) — PCR Braid

Alzheimer’s Disease — SCF-PCR Platform Mapped to FDA-Approved Therapeutics

Program: PROJECT NEURO-ORIGINIS

Platform Codename: SCF-PCR-ALZ-Ω

Therapeutic Architecture: Preventative → Curative → Restorative (PCR Braid)

Framework: Synergistic Compatibility Framework (SCF)

I. PLATFORM OBJECTIVE

To convert the three SCF API Discovery Profiles

NO-API-Θ1 — Neuroenergetic–Epigenomic Interceptor
NO-API-Θ2 — Neuroimmune–Network Stabilizer
NO-API-Φ-ALZ — Neurostructural Restoration Agent

into a translational SCF Biotech Systems Therapeutic Platform mapped to existing FDA-approved drug classes to enable:

IND-defensible translational programs
mechanistic validation using approved molecules
accelerated clinical development

The platform follows the SCF-PCR therapeutic braid, a systems-level intervention sequence addressing upstream disease drivers rather than downstream protein pathology.

II. SCF PATHOGENESIS MODEL FOR ALZHEIMER’S DISEASE

Etiopathogenic Core

Alzheimer’s prodrome arises from a cascade of systemic failures:

SCF Fault Tier	Biological Dysfunction	Clinical Outcome
Tier 1	Epigenomic plasticity collapse	Learning gene suppression
Tier 2	Mitochondrial bioenergetic failure	Neuronal energy deficit
Tier 3	Neuroimmune dysregulation	Microglial priming
Tier 4	Structural degeneration	Synaptic and myelin loss
Tier 5	Network desynchronization	Cognitive decline

The SCF platform intervenes upstream of amyloid/tau pathology.

III. SCF-PCR PLATFORM THERAPEUTIC ARCHITECTURE

Platform Structure

SCF Module	API	Biological Role	PCR Mode
Module A	Θ1	Epigenomic + mitochondrial interception	Preventative
Module B	Θ2	Immune resolution + network stabilization	Curative
Module C	Φ-ALZ	Structural and network restoration	Restorative

The modules form a biological cascade:

Energy restoration → Immune stabilization → Structural regeneration

IV. FDA DRUG MAPPING TO SCF PLATFORM

Existing FDA-approved drugs map mechanistically to SCF therapeutic nodes, enabling translational validation.

V. MODULE A — PREVENTATIVE INTERCEPTION ENGINE

(Mapped to NO-API-Θ1)

Biological Targets

Epigenomic drift
Chronobiologic disruption
Early autonomic instability

FDA Drug Class Mapping

Therapeutic Class	SCF Target	FDA-Approved Drugs
AhR pathway modulation	Reduce stress-viral transcription	Omeprazole
Epigenetic normalization	HDAC bias correction	Valproate, Vorinostat
Circadian rhythm restoration	Chronobiologic alignment	Melatonin, Tasimelteon
Early ANS stabilization	Reduce sympathetic overdrive	Propranolol, Ivabradine

Functional Outcome

Reopens transcriptional plasticity
prevents neuroimmune shock escalation
stabilizes neuronal metabolic environment

VI. MODULE B — CURATIVE CORE

(Mapped to NO-API-Θ2)

Biological Targets

mitochondrial collapse
autonomic dysregulation
neuroimmune misidentification

FDA Drug Class Mapping

Therapeutic Class	SCF Target	FDA-Approved Drugs
Mitochondrial metabolic restoration	ATP / NAD⁺ recovery	Nicotinamide riboside, CoQ10
Mitochondrial biogenesis signaling	PGC-1α activation	Metformin
Mitophagy regulation	Remove damaged mitochondria	Urolithin A (late-stage clinical)
Autonomic stabilization	Vagal tone recovery	Pyridostigmine, Midodrine
Neuroimmune tolerance restoration	Microglial reprogramming	Minocycline, Colchicine
Neuroendocrine regulation	HPA axis normalization	Mifepristone, Hydrocortisone

Functional Outcome

restores mitochondrial bioenergetics
resolves inflammatory signaling noise
stabilizes autonomic–immune governance

VII. MODULE C — RESTORATIVE ENGINE

(Mapped to NO-API-Φ-ALZ)

Biological Targets

synaptic degeneration
demyelination
circuit desynchronization

FDA Drug Class Mapping

Therapeutic Class	SCF Target	FDA-Approved Drugs
Anti-apoptotic metabolic stabilizers	Neuronal survival	Memantine
Neuroplasticity modulators	Learning restoration	Fluoxetine, D-cycloserine
Remyelination support	Oligodendrocyte recovery	Clemastine fumarate
Synaptic network stabilization	Circuit coherence	Donepezil
Prefrontal-ANS integration	Cognitive-autonomic coupling	Guanfacine

Functional Outcome

restores white-matter integrity
stabilizes synaptic architecture
improves neural network synchrony

VIII. INTEGRATED PLATFORM SYNERGY

SCF TRI-API SYSTEM

Platform Phase	Primary System	Expected Effect
Preventative	Epigenomic + metabolic	halt disease initiation
Curative	Neuroimmune + autonomic	reverse causal dysfunction
Restorative	Structural + network	rebuild cognitive resilience

SCF SYNERGY METRICS

Metric	Function
TSSM	Multi-axis therapeutic pressure
HSV-F²	Metabolic efficiency
SV-EQ	Target specificity
MGIS	Pharmacokinetic geometry alignment
SPCI	Safety compatibility

These metrics form the five-pillar SCF synergy architecture governing platform design.

IX. CLINICAL TRANSLATION STRATEGY

IND-Ready Development Model

Stage	Objective
Preclinical	Molecular validation and synergy modeling
IND	Regulatory authorization for human trials
Phase I	Safety and PK/PD
Phase II	Biomarker and cognitive efficacy
Phase III	Disease-modifying confirmation

The platform can leverage existing FDA-approved molecules for early translational testing, accelerating development timelines.

X. SYSTEMS-LEVEL THERAPEUTIC IMPACT

Expected clinical improvements include:

Domain	Impact
Cognitive	Stabilized memory and executive function
Neuroimmune	Reduced inflammatory tone
Structural	Preserved white-matter integrity
Bioenergetic	Restored neuronal ATP capacity
Network	Improved brain oscillatory coherence

XI. STRATEGIC ADVANTAGE

The SCF-PCR Alzheimer’s Platform offers several translational advantages:

Systems-level disease interception
Multi-pathway therapeutic synergy
FDA-mapped drug validation
High resistance barrier
IND-defensible mechanistic architecture

XII. PLATFORM SUMMARY

SCF-PCR-ALZ-Ω

A biotech systems therapeutic platform integrating:

epigenomic interception
mitochondrial restoration
immune stabilization
structural neural repair

into a Preventative–Curative–Restorative therapeutic cascade mapped to both novel SCF APIs and FDA-approved mechanistic drug classes.

This architecture enables rapid translational validation while supporting development of next-generation disease-modifying therapeutics for Alzheimer’s disease.

MASTER INDEX REGISTRY

Platform Code: SCF-PCR-ALZ-Ω

Program: PROJECT NEURO-ORIGINIS

Document Code: SCF-RD-ALZ-PCR-FDA-MAP-0002

Classification: SCF Biotech Systems Therapeutic Platform

Framework: Synergistic Compatibility Framework (SCF) — PCR Braid